Mounjaro Maximum Dose: The 15 mg Ceiling and How It Is Reached

Mounjaro max dosage per the current label

Section 2.1 of the Mounjaro label sets two ceilings, one per age group. There is no separate maximum for the second labelled use (reducing the risk of major cardiovascular events in adults with type 2 diabetes at high cardiovascular risk, added in August 2026); the same dosing scheme covers both indications.

Patient group	Starting dose	Step size	Maximum dose
Adults with type 2 diabetes	2.5 mg once weekly	2.5 mg, after at least 4 weeks	15 mg once weekly
Children 10 years and older with type 2 diabetes	2.5 mg once weekly	2.5 mg, after at least 4 weeks	10 mg once weekly

The pediatric indication was added in December 2025 and the Recommended Dosage section was revised in August 2026, so older copies of the label show only the adult figure.

No dose above 15 mg is approved. For overdose, the label advises contacting Poison Help (1-800-222-1222) and notes tirzepatide's half-life of about 5 days.

The escalation steps needed to reach the maximum dose of Mounjaro

The label's wording is conditional: increase by 2.5 mg "if additional glycemic control is needed", after at least 4 weeks on the current dose. Reaching 15 mg is not a scheduled destination; the prescriber decides whether each step happens at all.

Step	Weekly dose	Earliest weeks on this dose
1 (start)	2.5 mg	Weeks 1 to 4
2	5 mg	Weeks 5 to 8
3	7.5 mg	Weeks 9 to 12
4	10 mg (pediatric maximum)	Weeks 13 to 16
5	12.5 mg	Weeks 17 to 20
6	15 mg (adult maximum)	Week 21 onward

Any pause or held dose pushes the dates later. The label ties the slow climb directly to gastrointestinal side effects: the escalation schedule exists "to reduce the risk of gastrointestinal adverse reactions". The tirzepatide side effects guide shows how nausea, vomiting and diarrhea rates rise from the 5 mg to the 15 mg arms of the trials.

Mounjaro vs Zepbound: same molecule, same ceiling, different labels

Mounjaro and Zepbound are both tirzepatide from Eli Lilly, sold in the same six strengths. The maximum is 15 mg once weekly on both. What differs is the indication and how the label treats the lower doses.

Label point	Mounjaro	Zepbound
Indications	Type 2 diabetes (adults and children 10+); cardiovascular risk reduction in adults with type 2 diabetes	Weight reduction and long-term maintenance in adults; moderate to severe obstructive sleep apnea in adults with obesity
Maximum dose	15 mg weekly (adults); 10 mg weekly (children)	15 mg weekly, all indications
Escalation trigger	Only if more glycemic control is needed	Step to 5 mg after 4 weeks; further steps toward a chosen maintenance dose
Named maintenance doses	None named	5, 10 or 15 mg (weight); 10 or 15 mg (sleep apnea)
Pediatric use	Yes, 10 years and older	No

The Zepbound label states that it should not be combined with other tirzepatide-containing products or any GLP-1 receptor agonist, so the two brands are alternatives, not additive. See Zepbound dosing for its ladder, GLP-1 medications for the side-by-side view, and Ozempic max dose for semaglutide's ceiling.

What 15 mg looks like in each Mounjaro presentation

The dose is the same in each presentation; the volume and device are not.

Presentation	15 mg strength as labelled	Volume per 15 mg dose	Doses per unit
Single-dose pen	15 mg/0.5 mL	0.5 mL (whole pen)	1
Single-dose vial	15 mg/0.5 mL	0.5 mL	1
Multi-dose vial	60 mg/2.4 mL (25 mg/mL)	0.6 mL	4
Single-patient-use KwikPen	60 mg/2.4 mL (25 mg/mL)	Fixed dose, dialled to the stop	4

For vials, the label asks for a syringe suitable for the dose, for example a 1 mL syringe that can measure 0.5 mL or 0.6 mL, and a new syringe and needle every time; the dose is expressed in millilitres, not syringe units. The KwikPen delivers a fixed dose: after priming, the dose knob is turned until it stops. It is not designed to dial partial or extra doses.

Units at the maximum dose for compounded tirzepatide vials

Compounded tirzepatide is not Mounjaro: the FDA states compounded drugs are not FDA approved, and it has received more than 730 adverse event reports for compounded tirzepatide as of May 31, 2026, some linked to doses beyond the label. Concentrations vary between vials, so a "units" figure cannot be copied from one vial to another.

The arithmetic on a U-100 insulin syringe (100 units = 1 mL) is:

units = dose in mg ÷ (vial mg ÷ mL of liquid) × 100

The table below applies it to a 15 mg dose at three example concentrations. These are illustrations of the formula, not standard products or recommendations.

EXAMPLE vial	Concentration	Volume for 15 mg	U-100 units for 15 mg
30 mg in 3 mL	10 mg/mL	1.5 mL	150 units (more than one 1 mL syringe)
40 mg in 2 mL	20 mg/mL	0.75 mL	75 units
60 mg in 2 mL	30 mg/mL	0.5 mL	50 units

At a dilute concentration the maximum dose does not fit in a 100-unit syringe, and the same "50 units" is 15 mg in one example vial and 5 mg in another. Run your own vial through the tirzepatide calculator or the mg to mL converter, and read the syringe measurement guide before drawing anything.

When the ceiling is not the goal

The maximum dose is a limit, not a target. The label escalates only when more glycemic control is needed, and its adult trials (SURPASS-1 to SURPASS-5) studied 5 mg, 10 mg and 15 mg as separate fixed doses, with GI side-effect rates generally higher at higher doses. Whether to step up, hold or stop is a prescriber's decision.

Two label points apply at every step, including the last: oral contraceptive users are advised to switch method or add a barrier method for 4 weeks after each increase, and insulin or sulfonylurea doses may need lowering to avoid hypoglycemia. The tirzepatide dosage reference collects the label schedules in one place, and the cheapest tirzepatide guide covers access and cost questions.

Frequently Asked Questions

What is the maximum dose of Mounjaro?expand_more

15 mg injected subcutaneously once weekly for adults. For children 10 years and older with type 2 diabetes the maximum is 10 mg once weekly. Both figures are from the US prescribing information revised August 2026.

How long does it take to reach the Mounjaro max dose?expand_more

At least 20 weeks. The label starts at 2.5 mg and allows 2.5 mg increases only after at least 4 weeks on each dose, so the first 15 mg dose can be given in week 21 at the earliest, and only if more glycemic control is needed.

Is the Zepbound maximum dose different?expand_more

No. Zepbound is the same molecule and its maximum is also 15 mg once weekly for all of its indications. The labels differ in indication, named maintenance doses and pediatric use, not in the ceiling.

Can Mounjaro be taken more than once a week to get a higher dose?expand_more

The label is once weekly only. If the injection day changes, doses must be at least 3 days (72 hours) apart. The FDA has received adverse event reports linked to more frequent dosing and faster titration of compounded tirzepatide than the approved label allows.

How many units is 15 mg of tirzepatide?expand_more

It depends entirely on the concentration. On a U-100 syringe, units = mg ÷ (mg per mL) × 100. At an example concentration of 30 mg/mL, 15 mg is 50 units; at 10 mg/mL it is 150 units. Branded Mounjaro vials are dosed in mL: 0.5 mL for a single-dose vial, 0.6 mL from the multi-dose vial.

Worked Examples — Related Compound Protocols

Apply this guide to real protocols. Each linked page includes a live reconstitution calculator and titration schedule.

Tirzepatide dosage protocol

Tirzepatide is a once-weekly synthetic 39-amino-acid peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, manufactured by Eli Lilly and marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. In the Phase 3 SURMOUNT-1 trial of 2,539 adults without diabetes, tirzepatide 15 mg weekly produced a mean body-weight reduction of 20.9% at 72 weeks versus 3.1% with placebo, with 57% of participants losing at least 20% of body weight [1]. FDA approval for type 2 diabetes was granted in May 2022 and for chronic weight management in November 2023; tirzepatide is approved in the EU, UK, Japan, China and most major markets. Doses escalate monthly from 2.5 mg up to 5, 7.5, 10, 12.5 and a 15 mg maintenance ceiling.

Open protocolarrow_forward

Semaglutide dosage protocol

Semaglutide is a once-weekly GLP-1 receptor agonist developed by Novo Nordisk and marketed as Ozempic (type 2 diabetes), Wegovy (chronic weight management) and Rybelsus (oral T2D). In the pivotal Phase 3 STEP-1 trial of 1,961 adults with overweight or obesity without diabetes, weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight reduction of 14.9% at 68 weeks versus 2.4% with placebo, with 86% of treated participants achieving at least 5% loss [1]. Semaglutide is FDA approved for T2D (Ozempic, 2017), chronic weight management (Wegovy, 2021) and cardiovascular risk reduction in adults with obesity and established CVD (Wegovy expansion, 2024 — based on SELECT). Standard dosing is a 16-week titration: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, increasing every 4 weeks.

Open protocolarrow_forward

Retatrutide dosage protocol

Retatrutide (LY3437943) is a once-weekly triple-receptor agonist that activates the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors in a single peptide backbone, combining appetite suppression with thermogenic energy expenditure. In the Phase 2 TRIUMPH-2 trial published in NEJM, adults with obesity receiving 12 mg weekly achieved a placebo-adjusted mean weight reduction of 24.2% at 48 weeks, the largest pharmacologic weight loss reported to date and with no apparent plateau on the dose-response curve [1]. The 9 mg and 12 mg arms of the Phase 3 TRIUMPH-4 trial confirmed up to 28.7% weight reduction in adults with obesity and knee osteoarthritis at 68 weeks [2]. Retatrutide is investigational, not FDA approved, and remains restricted to clinical-trial use; it is sold by chemical suppliers as a research compound only.

Open protocolarrow_forward

Liraglutide dosage protocol

Liraglutide is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk under the code NN2211 and marketed as Victoza for type 2 diabetes and Saxenda for chronic weight management. It is an acylated analogue of native human GLP-1 sharing 97% sequence homology, modified with an Arg34-to-Lys substitution and a 16-carbon palmitoyl fatty-acid chain at Lys26 that drives reversible albumin binding and extends the half-life to roughly 13 hours, enabling daily subcutaneous dosing. The standard Liraglutide dosage for weight management titrates weekly from 0.6 mg to a 3.0 mg/day maintenance ceiling over five weeks; for glycemic control the Victoza ceiling is lower at 1.2 to a maximum 1.8 mg/day. Mechanistically it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic appetite centers to reduce energy intake. In the Phase 3 SCALE Obesity and Prediabetes trial, liraglutide 3.0 mg produced an 8.0% mean weight loss versus 2.6% with placebo at 56 weeks, and in the LEADER cardiovascular outcomes trial it cut major adverse cardiovascular events by 13% in high-risk type 2 diabetes. As a daily GLP-1 agonist it is pharmacologically distinct from weekly semaglutide and tirzepatide. Liraglutide is FDA- and EMA-approved; research-grade vials are sold for laboratory use only.

Open protocolarrow_forward

References & Citations

[1]
MOUNJARO (tirzepatide) injection, for subcutaneous use. US Prescribing Information, Eli Lilly and Company, revised August 2026 (DailyMed SPL version 40, published September 2, 2026). Sections 1, 2.1, 2.2, 3, 10 and 16.View source →
[2]
ZEPBOUND (tirzepatide) injection, for subcutaneous use. US Prescribing Information, Eli Lilly and Company, revised August 2026 (DailyMed SPL version 40, published September 2, 2026). Sections 1, 2.1 and 2.2.View source →
[3]
US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of October 1, 2026.View source →
[4]
US Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. July 26, 2024.View source →